Short course of letrozole before surgery may reveal Hormone-Sensitive breast cancers
NCT ID NCT03747042
First seen Apr 18, 2026 · Last updated Jun 20, 2026 · Updated 9 times
Summary
This completed Phase 2 trial gave postmenopausal women with hormone-sensitive breast cancer a short course of letrozole (7-30 days) before their scheduled surgery. The goal was to measure changes in a tumor marker called Ki67 to see which cancers are highly hormone-dependent. 61 women participated, and the study aimed to better understand how different breast cancers respond to hormone therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
letrozole
What this could lead to
If successful, this could help doctors identify which breast cancers are highly hormone-dependent and may respond best to letrozole treatment.
What could go wrong
This is a small, completed Phase 2 trial with only 61 participants, so results may not apply to all patients. It is a pre-surgical study, not designed to test long-term outcomes or cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.